Pfizer gains new cancer drugs in $11.4B purchase of Array BioPharma

Published



Pfizer, the firm behind prescription drugs from anxiety medication Zoloft to Viagra, agreed Monday to pay $11.4 billion for Array BioPharma and its cutting-edge treatments for colon and rectal cancers.

The Boulder, Colo.-based target’s portfolio includes the combination of Braftovi and Mektovi, drugs used for skin cancers that spread from one part of the body to another that are now being tested on colorectal tumors in more than two dozen clinical trials.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.